



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/565,183	01/18/2006	Paul Vermeij	1-2003.006 US	5236
31846	7590	09/03/2009		
Intervet/Schering-Plough Animal Health Patent Dept. K-6-1, 1990 2000 Galloping Hill Road Kenilworth, NJ 07033-0530			EXAMINER DEVI, SARVAMANGALA J N	
			ART UNIT 1645	PAPER NUMBER
			NOTIFICATION DATE 09/03/2009	DELIVERY MODE ELECTRONIC

**Please find below and/or attached an Office communication concerning this application or proceeding.**

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

lakeisha.robinson@spcorp.com  
jill.corcoran@spcorp.com  
patents@spcorp.com

<b>Office Action Summary</b>	<b>Application No.</b>	<b>Applicant(s)</b>	
	10/565,183	VERMEIJ, PAUL	
	<b>Examiner</b>	<b>Art Unit</b>	
	S. Devi, Ph.D.	1645	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

#### Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

#### Status

- 1) ☒ Responsive to communication(s) filed on 25 August 2009.
- 2a) ☐ This action is **FINAL**.                      2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

#### Disposition of Claims

- 4) ☒ Claim(s) 1-21 is/are pending in the application.
- 4a) Of the above claim(s) 4-9, 11-13 and 18-21 is/are withdrawn from consideration.
- 5) ☐ Claim(s) \_\_\_\_\_ is/are allowed.
- 6) ☒ Claim(s) 1-3, 10 and 14-18 is/are rejected.
- 7) ☐ Claim(s) \_\_\_\_\_ is/are objected to.
- 8) ☐ Claim(s) \_\_\_\_\_ are subject to restriction and/or election requirement.

#### Application Papers

- 9) ☒ The specification is objected to by the Examiner.
- 10) ☒ The drawing(s) filed on 18 January 2006 is/are: a) ☒ accepted or b) ☐ objected to by the Examiner.  
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

#### Priority under 35 U.S.C. § 119

- 12) ☒ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☒ All    b) ☐ Some \*    c) ☐ None of:
1. ☒ Certified copies of the priority documents have been received.
2. ☐ Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.
3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

\* See the attached detailed Office action for a list of the certified copies not received.

#### Attachment(s)

- |  |   |
|--|---|
| 1) <input checked="" type="checkbox"/> Notice of References Cited (PTO-892)            | 4) <input type="checkbox"/> Interview Summary (PTO-413)           |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948)   | Paper No(s)/Mail Date. _____                                      |
| 3) <input checked="" type="checkbox"/> Information Disclosure Statement(s) (PTO/SB/08) | 5) <input type="checkbox"/> Notice of Informal Patent Application |
| Paper No(s)/Mail Date <u>01/18/06</u> .  | 6) <input type="checkbox"/> Other: _____                          |

## **DETAILED ACTION**

### **Preliminary Amendment**

- 1) Acknowledgment is made of Applicants' preliminary amendment filed 01/18/06.

### **Election**

- 2) Acknowledgment is made of Applicants' election filed 06/25/09 in response to the written lack of unity mailed 06/23/09. Applicants have elected, with traverse, invention I, claims 1-3, 10 and 14-17 and the additional antigen species from a microorganism pathogenic to animals; the *E. coli* microorganism species; and the *E. coli* infection species. Because Applicants did not distinctly and specifically point out the supposed errors in the restriction requirement, the election has been treated as an election without traverse (M.P.E.P § 818.03(a)).

### **Status of Claims**

- 3) Claims 1-8 and 10-17 have been amended via the amendment filed 01/18/06.  
New claims 18-21 have been added via the amendment filed 01/18/06.  
Claims 1-21 are pending.  
Claim 4-9, 11-13 and 19-21 have been withdrawn from consideration as being directed to a non-elected species. See 37 C.F.R 1.142(b) and M.P.E.P § 821.03.  
Claims 1-3, 10 and 14-18 are under prosecution. A First Action on the Merits is issued for these claims.

### **Information Disclosure Statement**

- 4) Acknowledgment is made of Applicants' information disclosure statement filed 01/18/06. The information referred to therein has been considered and a signed copy of the same is attached to this Office Action.

### **Priority**

- 5) This application is the national stage 371 application of PCT/EP04/51522, filed 07/21/2003, which claims priority to the foreign application 03077266.9 filed 07/21/2003.  
It is noted that a copy of the foreign priority document is made of record in the instant application.

## **Objection to Specification**

**6)** The specification is objected to for the following reason(s):

(A) The use of trademark recitations has been noted in this application. For example, see page 20 for ‘Immobulon’ and ‘Coomassie Brilliant Blue’; and ‘Carbopol’ on page 16. Each trademark recitation must be capitalized. Although the use of trademarks is permissible in patent applications, the propriety nature of the trademarks should be respected and every effort made to prevent their use in any manner which might adversely affect their validity as trademarks. It is suggested that Applicants examine the whole specification and make necessary changes wherever trademark recitations appear.

(B) The instant application is informal in the format or arrangement of the specification. The following guidelines illustrate the preferred layout and content for patent applications. These guidelines are suggested for the Applicants’ use.

### **Content of Specification**

(a) Title of the Invention: See 37 C.F.R 1.72(a). The title of the invention should be placed at the top of the first page of the specification. It should be brief but technically accurate and descriptive, preferably from two to seven words.

(b) Cross-References to Related Applications: See 37 C.F.R 1.78 and M.P.E.P § 201.11.

(c) Statement Regarding Federally Sponsored Research and Development: See M.P.E.P § 310.

(d) Reference to a “Microfiche Appendix”: See 37 C.F.R 1.96(c) and M.P.E.P § 608.05. The total number of microfiche and the total number frames should be specified.

(e) Background of the Invention: The specification should set forth the Background of the Invention in two parts:

(1) Field of the Invention: A statement of the field of art to which the invention pertains. This statement may include a paraphrasing of the applicable U.S. patent classification definitions of the subject matter of the claimed invention. This item may also be titled "Technical Field."

(2) Description of the Related Art: A description of the related art known to the applicant and including, if applicable, references to specific related art and problems involved in the prior art which are solved by the applicant's invention. This item may also be titled "Background Art."

(f) Brief Summary of the Invention: A brief summary or general statement of the invention as set forth in 37 C.F.R. 1.73. The summary is separate and distinct from the abstract and is directed toward the invention rather than the disclosure as a whole. The summary may point out the advantages of the invention or how it solves problems previously existent in the prior art (and preferably indicated in the Background of the Invention). In chemical cases it should point out in general terms the utility of the invention. If possible, the nature and gist of the invention or the inventive concept should be set forth. Objects of the invention should be treated briefly and only to the extent that they contribute to an understanding of the invention.

(g) Brief Description of the Several Views of the Drawing(s): A reference to and brief description of the drawing(s) as set forth in 37 C.F.R. 1.74. The recitation 'Figure Legends' on page 9 of the specification should be replaced with --Brief Description of the Drawings'--.

(h) Detailed Description of the Invention: A description of the preferred embodiment(s) of the invention as required in 37 C.F.R. 1.71. The description should be as short and specific as is necessary to describe the invention adequately and accurately. This item may also be titled "Best Mode for Carrying Out the Invention." Where elements or groups of elements, compounds, and processes, which are conventional and generally widely known in the field of the invention described and their exact nature or type is not necessary for an understanding and use of the invention by a person skilled in the art, they should not be described in detail. However, where particularly complicated subject matter is involved or where the elements, compounds, or processes may not be commonly or widely known in the field, the specification should refer to another patent or readily available publication which adequately describes the subject matter.

(i) Claim or Claims: See 37 C.F.R. 1.75 and M.P.E.P. § 608.01(m). The claim or claims must commence on separate sheet. (37 C.F.R. 1.52(b)). Where a claim sets forth a plurality of elements or steps, each element or step of the claim should be separated by a line

indentation. There may be plural indentations to further segregate subcombinations or related steps.

(j) Abstract of the Disclosure: A brief narrative of the disclosure as a whole in a single paragraph of 250 words or less on a separate sheet following the claims.

(k) Drawings: See 37 C.F.R 1.81, 1.83-1.85, and M.P.E.P § 608.02.

(l) Sequence Listing: See 37 C.F.R 1.821-1.825.

(C) The disclosure is objected to because it contains an embedded hyperlink and/or other form of browser-executable code. See paragraph bridging pages 13 and 14 of the specification. Applicant is required to delete the embedded hyperlink and/or other form of browser-executable code. See MPEP § 608.01.

(D) The nucleotide sequences depicted in Table 1 are 10 nucleotides or longer in length. Yet these sequences are not identified by specific SEQ ID numbers as required under 37 C.F.R 1.821 through 1.825. Any sequences recited in the instant specification, which are encompassed by the definitions for nucleotide and/or amino acid sequences as set forth in 37 C.F.R. 1.821(a)(1) and (a)(2) must comply with the requirements of 37 C.F.R 1.821 through 1.825. Note that branched sequences are specifically excluded from this definition.

APPLICANT MUST COMPLY WITH THE SEQUENCE RULES WITHIN THE SAME TIME PERIOD AS IS GIVEN FOR RESPONSE TO THIS ACTION, 37 C.F.R 1.821 - 1.825. Failure to comply with these requirements will result in ABANDONMENT of the application under 37 C.F.R 1.821(g).

### **Rejection(s) under 35 U.S.C. 112, Second Paragraph**

**7)** The following is a quotation of the second paragraph of 35 U.S.C. § 112:

The specification shall conclude one or more claims particularly pointing out and distinctly claiming the subject matter which the Applicant regards as his/her invention.

**8)** Claims 1-3, 10 and 14-18 are rejected under 35 U.S.C § 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which Applicants regard as the invention.

(a) Claim 1 is indefinite in the limitations: ‘an A1-part’ and ‘an A2-part’, because it is unclear what precise part of A1 and A2 is encompassed. Does a dipeptide from A1 of Shiga toxin

or Shiga-like-toxin, or a single amino acid from A2 of *E. coli* heat-labile enterotoxin qualify as ‘an A1-part’ or ‘an A2-part’?

(b) Claim 14 is vague and indefinite in the limitation ‘derived’, because it is unclear what is encompassed in this limitation. Does the process of ‘deriving’ encompass extraction, isolation, recombinant production, separation, purification, expression on cell surface, or structural modification?

(c) Claim 16 is vague and indefinite in the recitation ‘effective amount’ because it is a relative term. The term ‘effective’ is not specifically defined by the claim, the specification does not provide a standard for ascertaining the requisite degree, and one of ordinary skill in the art would not be reasonably appraised of the scope of the claim. What amount qualifies as an ‘effective’ amount, and in what capacity the amount is ‘effective’, is unclear.

(d) Claims 2, 3, 10 and 14-18, which depend directly or indirectly from claim 1, are also rejected as being indefinite because of the indefiniteness identified above in the base claim.

### **Rejection(s) under 35 U.S.C § 102**

**9)** The following is a quotation of the appropriate paragraphs of 35 U.S.C. § 102 that form the basis for the rejections under this section made in this Office Action:

A person shall be entitled to a patent unless –

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

**10)** Claims 1, 10, 14 and 16-18 are rejected under 35 U.S.C § 102(b) as being anticipated by Holmgren *et al.* (US 6,019,973).

It is noted that the limitation ‘an A1-part’ or ‘an A2-part’ lacks a structure limit, size limit, or a length limit, and therefore encompasses a single amino acid or a dipeptide.

The transitional limitation ‘comprising’ is inclusive or open-ended and does not exclude additional, unrecited elements or method steps. *Moleculon Research Corp. v. CBS, Inc.*, 793 F.2d 1261, 229 USPQ 805 (Fed. Cir. 1986); *In re Baxter*, 656 F.2d 679, 686, 210 USPQ 795, 803 (CCPA 1981); and *Ex parte Davis*, 80 USPQ 448, 450 (Bd. App. 1948) (‘comprising’ leaves ‘the claim open for the inclusion of unspecified ingredients even in major amounts’).

Holmgren *et al.* disclosed a hybrid bacterial toxin that comprises the contiguous amino acids Ser Tyr as well as the contiguous amino acids Ile Ser therein, which are identical to the amino acids Ser Tyr as well as the amino acids Ile Ser depicted at positions 21 and 22 as well as positions 251 and 252 of the SEQ ID NO: 2 of the instant invention, i.e., 'an A1-part' and 'an A2-part' recited in instant claim 1. An immunogenic protein comprising the same and an immunoreactive amino acid sequence (i.e., additional antigen) of a prokaryotic, eukaryotic cell, or a virus and a vaccine comprising an immunologically effective amount of the same, wherein the vaccine is against enterotoxin-induced illness are taught. A method of making the vaccine is taught. A method of reducing the incidence of enterotoxin-induced illness such as diarrhea and a method of treating or preventing an enterotoxin-induced illness in an animal or human individual comprising administration to said individual an immunologically effective amount of an immunogenic protein comprising the hybrid molecule. See Figures 2a and 2b; claims 1-3 and 6-13; lines 41-60 in column 3; columns 5 and 6; lines 1-39 in column 7; Tables 1 and 2; sections 'Materials and Methods' and 'Preparation of hybrid CTB/LTB molecules of the invention'.

Claims 1, 10, 14, 16 and 17 are anticipated by Holmgren *et al.*

### **Claim(s) Objection(s)**

**11)** Claims 1, 3 and 16 are objected to for the following reasons:

Claims 1, 3 and 16 are objected to for the non-italicized limitation: 'Escherichia coli'. To be consistent with the italicized limitation used in claim 15, it is suggested that Applicants replace the above-identified limitation with the limitation --*Escherichia coli*--.

### **Remarks**

**12)** Claims 1-3, 10 and 14-18 stand rejected.

**13)** Papers related to this application may be submitted to Group 1600, AU 1645 by facsimile transmission. The Fax number for submission of amendments, responses and/or papers is (571) 273-8300, which receives transmissions 24 hours a day and 7 days a week.

**14)** Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAG or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR



system, see <http://pair-direct.uspto.Mov>. Should you have questions on access to the Private PAA system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (in USA or CANADA) or 571-272-1000.

**15)** Any inquiry concerning this communication or earlier communications from the Examiner should be directed to S. Devi, Ph.D., whose telephone number is (571) 272-0854. A message may be left on the Examiner's voice mail system. The Examiner can normally be reached on Monday to Friday from 7.15 a.m. to 4.15 p.m. except one day each bi-week, which would be disclosed on the Examiner's voice mail system.

If attempts to reach the Examiner by telephone are unsuccessful, the Examiner's Supervisor, Robert Mondesi, can be reached on (571) 272-0956.

/S. Devi/  
Primary Examiner  
AU 1645

August, 2009